Massachusetts Wealth Management’s iShares Biotechnology ETF IBB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$846K Buy
4,446
+223
+5% +$38.3K 0.32% 74
2026
Q1
$713K Buy
4,223
+208
+5% +$35.6K 0.31% 76
2025
Q4
$678K Buy
4,015
+762
+23% +$124K 0.32% 77
2025
Q3
$470K Buy
3,253
+450
+16% +$61.4K 0.23% 79
2025
Q2
$355K Buy
2,803
+313
+13% +$38.4K 0.2% 79
2025
Q1
$318K Buy
2,490
+445
+22% +$60.3K 0.22% 71
2024
Q4
$270K Buy
+2,045
New +$287K 0.17% 83

Other funds holding IBB

Massachusetts Wealth Management's IBB Position: Q2 2026 in Review

Massachusetts Wealth Management increased its iShares Biotechnology ETF (IBB) stake by 5.3% in Q2 2026, buying an estimated $38.3K and bringing the position to 4,446 shares worth $846K. The position accounts for 0.32% of the portfolio, ranked #74.

Massachusetts Wealth Management first reported a position in IBB in Q4 2024 and has held it in 7 quarters since. 956 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Massachusetts Wealth Management held 4,446 shares of iShares Biotechnology ETF worth $846K as of Q2 2026.
  • Massachusetts Wealth Management bought 223 iShares Biotechnology ETF shares in Q2 2026, an estimated $38.3K.
  • iShares Biotechnology ETF made up 0.32% of Massachusetts Wealth Management's portfolio in Q2 2026, its #74 holding.
  • Massachusetts Wealth Management first reported a position in iShares Biotechnology ETF in Q4 2024 and has held it in 7 quarters since.
  • 956 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Massachusetts Wealth Management's 13F filing for Q2 2026, filed 3 Aug 2026.